A Rutgers review argues that the same metabolic and “anti-aging” drugs now flooding clinics — GLP-1 agonists, metformin, SGLT-2 inhibitors and others — appear to protect the aging eye against glaucoma and retinal disease, even as one of them, semaglutide, carries an unresolved signal for a rare, blinding optic-nerve injury.
The eye is increasingly being read as a window onto systemic aging, and the drugs people take to slow that aging may be reshaping ocular fate in ways nobody planned for. That is the central message of a new review from Rutgers New Jersey Medical School, which surveys eleven classes of “geroprotective” compounds and asks a deceptively simple question: when a patient walks into an ophthalmology clinic already on Ozempic, metformin, or an SGLT-2 inhibitor, is their vision safer or more at risk?
The authors frame glaucoma, age-related macular degeneration, diabetic retinopathy and retinal vein occlusion not as isolated eye diseases but as a single family of neuro-microvascular disorders driven by the universal machinery of aging — mitochondrial decline, oxidative stress, chronic inflammation, and the slow death of retinal ganglion cells. Drugs that tune the master longevity switches (AMPK up, mTOR down) should, in theory, defend the retina just as they defend the heart and brain.
The accumulating real-world data broadly support that optimism. Multiple large database studies link GLP-1 agonists, metformin, SGLT-2 inhibitors, taurine and NAD+ precursors to lower glaucoma incidence or reduced intraocular pressure. SGLT-2 inhibitors emerge as the cleanest actor in the file — protective signals across glaucoma, retinopathy and AMD, with essentially no attributed ocular harm.
But the review’s real tension sits with GLP-1 agonists. The same molecule celebrated for shielding optic nerves was tied in 2024 to a roughly fourfold higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) — a sudden, irreversible loss of vision. The signal remains hotly contested: some later cohorts replicate it, others find nothing. Regulators have split. Europe’s EMA now lists NAION as a “very rare” side effect and advises stopping the drug if it occurs; American ophthalmology bodies counsel individualized judgment and monitoring rather than reflexive discontinuation.
The honest bottom line, the authors concede, is that almost none of this rests on prospective trials with predefined eye endpoints. The evidence is retrospective, confounded by the diabetes the drugs are treating, and occasionally contradictory. The FOCUS trial, still running, may finally settle the retinopathy question for semaglutide. Until then, the message to clinicians is vigilance: a generation of longevity-adjacent drugs is being prescribed at unprecedented scale, and the eye is one of the organs we understand least about what they actually do.
Actionable Insights (≈200 words)
The practical takeaways are real but modest, and the effect sizes the review actually reports are thin — most “reduced risk” claims in the paper are stated qualitatively, without hazard ratios. What you can extract:
- GLP-1 NAION risk: ~4x relative risk (Hathaway 2024, single-center retrospective). Crucially, this is a relative figure on a rare event. Background NAION incidence is roughly 2–10 per 100,000/year, so even a quadrupling implies a small absolute increase (order of tens per 100,000). This is a “be aware, don’t panic” magnitude. [Confidence: Medium on the relative estimate; the signal itself is contested]
- SGLT-2 inhibitors look like the safest ocular bet among the metabolic geroprotectors — protective or neutral across every endpoint, zero attributed harm class-wide. If choosing among agents with an eye to ocular safety, this is the standout. [Confidence: Medium]
- Taurine and NAD+ precursors have mechanistic and preclinical support for retinal ganglion cell protection but no human ocular efficacy data — supplement at your own evidentiary risk.
- Cannabis is not glaucoma therapy: THC’s IOP drop lasts only hours; major societies reject it.
Source:
- Paywalled Paper: Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, for Ocular Health
- Institution: Department of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark
- Country: USA
- Journal: Journal of Ocular Pharmacology and Therapeutics (Mary Ann Liebert / Sage)
- Impact Evaluation: The impact score of this journal is 2.25 (2024 JIF; CiteScore 3.5, SJR 0.597, Q2 in ophthalmology), evaluated against a typical high-end range of 0–60+ for top general science and 10–25+ for elite specialty clinical journals (e.g., Ophthalmology, JAMA Ophthalmology), therefore this is a Low-to-Medium impact journal